Clamox 875 mg+125 mg (Tablet)

Indications

• Short-term treatment of bacterial infections at various sites including upper respiratory tract, lower respiratory tract, genito-urinary tract, skin and soft tissue, bone and joint, and other infections

Composition

• 375 mg tablet contains Amoxicillin 250 mg and Clavulanic Acid 125 mg
• 625 mg tablet contains Amoxicillin 500 mg and Clavulanic Acid 125 mg
• 1 gm tablet contains Amoxicillin 875 mg and Clavulanic Acid 125 mg
• Powder for Suspension contains Amoxicillin 125 mg and Clavulanic Acid 31.25 mg
• Powder for Suspension (Forte) contains Amoxicillin 400 mg and Clavulanic Acid 57.5 mg
• 1.2 gm Injection contains Amoxicillin Sodium (equivalent to Amoxicillin 1 gm) and Clavulanate Potassium (equivalent to Clavulanic Acid 200 mg)
• 0.6 gm Injection contains Amoxicillin Sodium (equivalent to Amoxicillin 500 mg) and Clavulanate Potassium (equivalent to Clavulanic Acid 100 mg)

Pharmacology

• Broad spectrum of bactericidal activity against many Gram-positive and Gram-negative microorganisms but susceptible to degradation by beta-lactamases
• Clavulanic acid inactivates a wide range of beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins
• Peak serum levels of both components occur about one hour after oral administration

Dosage

• Adults and children over 12 years have different dosage recommendations based on the tablet, suspension, forte suspension, and IV injection forms

Administration

• Oral dosage form can be taken without regard to meals, while IV injection form should be administered intravenously by injection or slow intravenous infusion

Interaction

• Prolongation of bleeding time and prothrombin time reported in some patients receiving Co-amoxiclav, may reduce the efficacy of oral contraceptives, and caution is advised with concomitant use of allopurinol

Contraindications

• Contraindicated in individuals with history of Penicillin hypersensitivity or previous history of Co-amoxiclav or Penicillin-associated cholestatic jaundice

Side Effects

• Uncommon and mainly of a mild and transitory nature such as diarrhea, pseudomembranous colitis, indigestion, nausea, vomiting, candidiasis, hepatitis, cholestatic jaundice, urticarial and erythematous rashes

Pregnancy & Lactation

• Animal studies showed no teratogenic effect, limited use in human pregnancy, and trace quantities of Amoxicillin detected in breast milk during lactation

Precautions & Warnings

• Should be used with care in patients on anticoagulation therapy or with severe hepatic dysfunction, and dosage should be adjusted in patients with moderate or severe renal impairment

Use in Special Populations

• Dosage adjustments for patients with renal impairment and hepatic impairment should be administered with caution

Overdose Effects

• Problems of overdose are unlikely but may result in gastrointestinal symptoms and fluid and electrolyte imbalances, and may be removed from the circulation by haemodialysis

Therapeutic Class

• Belongs to the therapeutic class of broad spectrum penicillins

Reconstitution

• The 1.2 gm IV injection can be reconstituted by dissolving the powder in 20 ml Water for Injection BP and should not be mixed with certain solutions

Storage Conditions

• Should be stored below 25°C, protected from light and moisture, reconstituted suspension should be kept in the refrigerator and used within 7 days, reconstituted vial must be used within 20 minutes

Related Brands

• Co-Clav (125 mg+31.25 mg)/5 ml (Powder for Suspension) - ad-din-pharmaceuticals-ltd
• Co-Clav 500 mg+125 mg (Tablet) - ad-din-pharmaceuticals-ltd
• Mimoxclav 500 mg+125 mg (Tablet) - albion-laboratories-limited
• Fortimox 500 mg+125 mg (Tablet) - kumudini-pharma-ltd
• Fimoxyclav ES (600 mg+42.9 mg)/5 ml (Powder for Suspension) - synovia-pharma-plc